Clearnote Health
Samuel Levy is the CEO & Chief Scientific Officer at Bluestar Genomics. Samuel has more than 20 years of scientific leadership in genomics and molecular diagnostic development. Previously, he was Founder and Chief Scientific Officer at Impact Genomics (dba Lexent Bio).
Samuel earned his Ph.D. in Cell Biology and Computer Simulation from the University of Bristol in 1986.
Clearnote Health
ClearNote Health (formerly Bluestar Genomics) – Cancer detection company enabling people at risk for high-mortality cancers to live longer, healthier lives. They focus on developing non-invasive tests to detect cancer through a standard blood draw earlier than existing methods by harnessing the power of epigenomics. They apply their proprietary epigenomic platform, combining biology and artificial intelligence, to identify DNA-based changes in biology as cancer develops. With lead programs in non-invasive early detection of pancreatic and ovarian cancers in patients at the highest risk for these diseases. Headquartered in the U.S, the company’s CLIA and CAP-accredited laboratory is located in San Diego, Calif., with additional presence in the San Francisco Bay Area and internationally.